TY - JOUR
T1 - The genetics of kidney stone disease and nephrocalcinosis
AU - Singh, Prince
AU - Harris, Peter C.
AU - Sas, David J.
AU - Lieske, John C.
N1 - Funding Information:
J.C.L. receives consulting fees from the American Board of Internal Medicine, Alnylam, OxThera, Dicerna, Synlogic, Orfan and Novobiome, and grant support from Alnylam, Allena, Retrophin, OxThera, NIDDK and Dicerna. D.J.S. has received consulting fees from Advicenne, and lecture fees from Retrophin. P.C.H. receives consulting fees from Otsuka Pharmaceuticals, Mitobridge, Regulus, Vertex Pharmaceuticals and Caraway Therapeutics. He has received grant support from Otsuka Pharmaceuticals, Navitor, Acceleron and Jemincare. P.S. has no competing interests.
Publisher Copyright:
© 2021, Springer Nature Limited.
PY - 2022/4
Y1 - 2022/4
N2 - Kidney stones (also known as urinary stones or nephrolithiasis) are highly prevalent, affecting approximately 10% of adults worldwide, and the incidence of stone disease is increasing. Kidney stone formation results from an imbalance of inhibitors and promoters of crystallization, and calcium-containing calculi account for over 80% of stones. In most patients, the underlying aetiology is thought to be multifactorial, with environmental, dietary, hormonal and genetic components. The advent of high-throughput sequencing techniques has enabled a monogenic cause of kidney stones to be identified in up to 30% of children and 10% of adults who form stones, with ~35 different genes implicated. In addition, genome-wide association studies have implicated a series of genes involved in renal tubular handling of lithogenic substrates and of inhibitors of crystallization in stone disease in the general population. Such findings will likely lead to the identification of additional treatment targets involving underlying enzymatic or protein defects, including but not limited to those that alter urinary biochemistry.
AB - Kidney stones (also known as urinary stones or nephrolithiasis) are highly prevalent, affecting approximately 10% of adults worldwide, and the incidence of stone disease is increasing. Kidney stone formation results from an imbalance of inhibitors and promoters of crystallization, and calcium-containing calculi account for over 80% of stones. In most patients, the underlying aetiology is thought to be multifactorial, with environmental, dietary, hormonal and genetic components. The advent of high-throughput sequencing techniques has enabled a monogenic cause of kidney stones to be identified in up to 30% of children and 10% of adults who form stones, with ~35 different genes implicated. In addition, genome-wide association studies have implicated a series of genes involved in renal tubular handling of lithogenic substrates and of inhibitors of crystallization in stone disease in the general population. Such findings will likely lead to the identification of additional treatment targets involving underlying enzymatic or protein defects, including but not limited to those that alter urinary biochemistry.
UR - http://www.scopus.com/inward/record.url?scp=85121284838&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121284838&partnerID=8YFLogxK
U2 - 10.1038/s41581-021-00513-4
DO - 10.1038/s41581-021-00513-4
M3 - Review article
C2 - 34907378
AN - SCOPUS:85121284838
SN - 1759-5061
VL - 18
SP - 224
EP - 240
JO - Nature Reviews Nephrology
JF - Nature Reviews Nephrology
IS - 4
ER -